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Capsule summary 38 
This mouse study demonstrates that repetitive inhalation of a single major house dust mite (HDM) 39 
allergen prevents HDM-induced allergic asthma development through suppressing the function of 40 
lung dendritic cells, thus providing an alternative to classical allergen-specific immunotherapy.  41 
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To the Editor, 45 
The prevalence of allergic diseases is increasing, urging new ways of prevention. Allergen 46 
immunotherapy (AIT) is currently the only clinical intervention that can alter the natural course of 47 
allergy and can offer long-term clinical benefit. Although AIT is traditionally used as treatment in 48 
patients with established disease, the National Institute of Health Immune Tolerance Network (ITN) 49 
has proposed that prophylactic AIT could also be used as primary prevention for new sensitizations 50 
and allergic disease, in high risk children born to atopic parents and with a personal history of atopic 51 
dermatitis and/or food allergen sensitization in early life1. AIT involves the repeated administration of 52 
allergen extracts, leading to the induction of an ill-defined state of systemic allergen-specific 53 
immunological tolerance that is associated with decreased symptom scores, particularly in allergic 54 
rhinitis patients, but less so in asthmatics2. While current AIT involves the subcutaneous or sublingual 55 
administration of crude allergen extracts, regimens based on natural routes of mucosal allergen 56 
administration and defined single allergens might improve success rate. Several studies have 57 
suggested that the natural route of allergen exposure (e.g. ingestion of peanut allergen in infants, 58 
bee stings in bee keepers, inhalation of high doses of cat allergens in pet owners) can be very 59 
successful in preventing the onset of clinical allergies3-5. The exposure to immunodominant allergens 60 
in these studies, such as Arah6 peanut allergen in breast milk, phospholipase A2 in bee venom, and 61 
Feld1 cat allergen in house dust, suggests that the same allergens that can cause disease are also 62 
best at inducing tolerance via the natural route of exposure.  63 
To improve the success rate of prophylactic AIT in asthma, we hypothesized that inhalation of Derp2, 64 
a major immunodominant house dust mite (HDM) allergen, would prevent the onset of HDM 65 
sensitization and HDM-induced asthma. Recombinant Derp2 was produced in the yeast Pichia 66 
pastoris, and was given as prophylactic AIT intranasally to naive C57Bl/6J mice every other day for a 67 
period of 15 days, prior to intratracheal (i.t.) sensitization to the full HDM extract, and HDM extract 68 
airway challenges (Fig 1a). In mice treated with sham PBS AIT, HDM sensitization and challenges 69 
induced robust asthma features, including airway and tissue eosinophilia (Fig 1b-c), goblet cell 70 
metaplasia (Fig 1b), T and B cell influx in the bronchoalveolar space (BAL) (Fig 1c), T helper 2 (Th2) 71 
cytokine production by lung-draining lymph node (LDLN) cells (Fig 1d), immunoglobulin (Ig)E 72 
synthesis (Fig 1e) and bronchial hyperreactivity (BHR) to methacholine (Fig 1f). These allergic asthma 73 
features were almost completely abolished in mice that received active Derp2 AIT (Fig 1b-f). To 74 
address if intranasal Derp2 AIT would also be effective in a more therapeutic secondary prevention 75 
setting, mice were first sensitized to HDM extract, and after one week treated for 17 days with Derp2 76 
AIT, followed by HDM airway challenges.  In this setting too, Derp2 AIT prevented development of 77 
the salient features of asthma, among which eosinophilia, Th2 cytokine production in LDLNs, and BHR 78 
(p<0.09) (Fig 1g-i).  79 
We next sought for the immunological mechanism(s) of prophylactic AIT. In the active Derp2 AIT 80 
group, we observed increased concentrations of HDM-specific IgG2c and IgG1 in serum, and of HDM-81 
specific IgA in BAL fluid (Fig 1e). In humans, successful AIT is often accompanied by increased titers of 82 
IgG1, IgG4 and/or IgA6. However, despite the increase in several Igs, our prophylactic Derp2 AIT did 83 
not require B cells, since the effects of AIT on lung eosinophilia and Th2 cytokine production were 84 
preserved in Mb1Cre x Rosa26-Lox-Stop-LoxDTA mice genetically lacking B cells (Fig E1). 85 
The generation of adaptive type 2 immunity to HDM depends on allergen presentation by type 2 86 
conventional dendritic cells (cDC2s), which bridge innate and adaptive immunity. The capacity of 87 
lungs DCs to take up HDM allergen in the lungs and transport it to the LDLNs was not reduced by 88 
prophylactic Derp2 AIT (Fig E2a), and there were only small effects of Derp2 AIT on the expression of 89 
the co-stimulatory molecules CD80 and CD86 on cDC1s and cDC2s (Fig E2b). To study the impact of 90 
Derp2 AIT on functional allergen presentation by DCs, we used TCR-transgenic 1-DER mice in which 91 
all CD4+ T cells react to an immunodominant peptide of Derp17. CD4+ 1-DER T cells were transferred 92 
to mice previously treated with Derp2 or sham PBS AIT, and their active division induced by HDM 93 
extract inhalation. 4, 7 and 10 days after HDM inhalation, the LDLNs of sham treated mice contained 94 
highly proliferating 1-DER T cells, yet proliferation was strongly reduced in mice receiving Derp2 AIT 95 
(Fig. 2a-b). Derp2 AIT also suppressed IL-5, IL-13, and IL-10 secretion (Fig. 2c), and Gata3 mRNA 96 
expression (Fig E2c) by LDLN cells, and reduced the total and effector CD44+CD62L- 1-DER T cell 97 
numbers in lung tissue (Fig 2d-e). Similar effects of Derp2 AIT on 1-DER T cell activity were observed 98 
when i.t. Derp1 was administered instead of HDM to trigger 1-DER T cell responses (data not shown).  99 
In support of a role for Derp2 AIT-induced suppression of cDC2 functions, we found that the adoptive 100 
transfer of in vivo HDM-primed cDC2, obtained from LDLNs of mice that had never been exposed to 101 
Derp2 AIT, was sufficient to break the tolerant state induced by prophylactic Derp2 AIT (Fig. 2f). 102 
Furthermore, vice versa, LDLN cDC2s from mice undergoing prophylactic Derp2 AIT and then exposed 103 
to a single HDM extract inhalation, were less efficient in priming type 2 immunity upon adoptive 104 
transfer to naive hosts (Fig E2d). In another set of experiments, cDCs were sorted from the LDLNs of 105 
sham or Derp2 AIT mice that were primed with a single Derp1 protein inhalation, and were co-106 
cultured with 1-DER T cells ex vivo. cDC2s from the Derp2 AIT group induced less 1-DER T cell 107 
proliferation than cDC2s from the sham AIT group (Fig 2g). T cell proliferation induced by cDC1s was 108 
not influenced by Derp2 AIT (data not shown).  109 
We finally addressed the mechanism of the reduced cDC2-mediated antigen presentation in mice 110 
treated with prophylactic Derp2 AIT. In response to HDM inhalation, cDC2s are activated to perform 111 
this function through the epithelial release of DC-instructing cytokines8. We therefore measured 112 
whether prophylaxis with Derp2 affected the release of pro-allergic cytokines and chemokines 113 
following a first inhalation of whole HDM allergen extract. In the sham AIT group, a single dose of i.t. 114 
instilled HDM extract led to an increased production of MCP-1, KC, IL-1, and GM-CSF, in lungs, 115 
compared to i.t. instilled PBS (Fig 2h). Prophylactic Derp2 AIT only significantly reduced the 116 
production of GM-CSF, a cytokine that has been shown to break inhalation tolerance by activating 117 
DCs9. To study the functional importance of reduced GM-CSF release in the tolerance mediated by 118 
Derp2, mice treated with sham or Derp2 AIT and sensitized and challenged with HDM extract, were 119 
supplemented i.t with recombinant GM-CSF at the time of sensitization. Strikingly, Derp2 AIT mice 120 
that received GM-CSF at the time of HDM sensitization were no longer protected from allergy 121 
development, as assessed by their development of a robust BAL eosinophilia (Fig 2i). We found 122 
comparable results in a secondary prevention setting (Fig E3a). Similarly, the effect of prophylactic 123 
Derp2 AIT on 1-DER T cell division was also rescued by GM-CSF supplementation (Fig 2j and Fig E3b). 124 
In conclusion, our findings in mice show that prophylactic exposure to the single immunodominant 125 
HDM allergen Derp2 via the airways offers an alternative way to prevent respiratory allergy to the 126 
complex allergen HDM, by suppressing GM-CSF-driven activation of lung cDC2s. 127 
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Figure legends  180 
Figure 1: Prophylactic Derp2 inhalation prevents HDM-induced allergic asthma development. (a) 181 
Experimental setup for Fig 1b-f. (b) Mucus production (purple, upper panel), and eosinophils (yellow, 182 
lower panel) in lungs. (c) Immune cells in bronchoalveolar lavage (BAL) fluids. (d) Cytokine production 183 
by HDM-restimulated lung-draining lymph node (LDLN) cells. (e) Immunoglobulins (Igs) in serum (IgE, 184 
IgG1, IgG2c), or BAL (IgA). (f) Airway resistance in response to methacholine (Mch). (g-i) Secondary 185 
prevention setting. (g) Immune cells in BAL. (h) Cytokine production by HDM-restimulated LDLN cells. 186 
(i) Airway resistance in response to Mch. Results are representative of 1 (b), 2 (e), 4 (d) or 6 (c), or 187 
pooled from 2 (f, i) or 3 (g, h) independent experiments, with n = 4-7 (b-f) or 3-6 (g-i) mice/group for 188 
single experiments. Data are shown as means ± SEM, or in (f) and (i) as predictions of means ± SEM 189 
obtained from repeated measurement analysis using residual maximum likelihood (REML). *p<0.05, 190 
**p<0.01, ***p<0.001. OD: optical density at 650 nm/850 nm. 191 
Figure 2: Prophylactic Derp2 inhalation suppresses cDC2-mediated Th2 responses by blocking GM-192 
CSF release. (a-e) Derp2 or sham PBS mice received CFSE-labeled 1-DER T cells intravenously (iv) and 193 
HDM intratracheally (i.t.), and were analyzed 4, 7 or 10 d later. (a) Cell division profiles, and (b) 194 
proliferation parameters, of tissue-resident (CD45iv injected (iv)-) 1-DER T cells in lung-draining lymph 195 
nodes (LDLNs). (c) Cytokine production by HDM-restimulated LDLN cells. (d) Number and (e) 196 
phenotype of tissue-resident lung 1-DER T cells. (f) Treatment as in Fig 1a, with 2 groups of mice i.t. 197 
sensitized with donor HDM-primed cDC2s instead of HDM. Immune cells in bronchoalveolar lavage 198 
(BAL) fluids. (g) V450-labeled 1-DER T cells co-cultured with LDLN cDC2s of Derp2 or sham PBS mice 199 
i.t. instilled with Derp1. Cell division profiles, expansion indexes, and counts of 1-DER T cells. (h) 200 
Cytokines and chemokines in lung tissue of Derp2 or sham PBS mice 2 h after HDM instillation. (i) 201 
Treatment as in Fig 1a, with 1 group of mice i.t. sensitized with HDM + GM-CSF. BAL immune cells. (j) 202 
Derp2 or sham PBS mice received CFSE-labeled 1-DER T cells iv and Derp1 with or without GM-CSF 203 
i.t.. Proliferation parameters of LDLN 1-DER T cells. Results are representative of 2 (f-h, j) or 3 (a-e), or 204 
pooled from 2 (i) independent experiments, with n = 4-8 (a-f, h-j) mice/group or 2-3 (g) 205 
replicates/group for single experiments. Shown as means ± SEM (or ± SD in (g)). *p<0.05, **p<0.01, 206 
***p<0.001, ****p<0.0001.  207 
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